GlassScriptPhysician profile
Charles R May
NPI 1245268531
$9,397.90
in general payments reported to CMS, 2019-2025
30 companies · $1,677 in 2025
The $1,677 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,144 · 2020: $962 · 2021: $1,211 · 2022: $1,724 · 2023: $1,635 · 2024: $1,046 · 2025: $1,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,357.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,095.40 | 2019-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $733.09 | 2019-2024 | Jornay Pm |
| Abbvie INC. | $714.38 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $702.45 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $678.44 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $656.95 | 2020-2025 | Caplyta |
| Corium, LLC | $630.38 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $605.90 | 2020-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $442.33 | 2019-2022 | |
| Axsome Therapeutics, INC. | $431.15 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $408.54 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $353.04 | 2019-2023 | Austedo, Austedo Xr |
| Lundbeck LLC | $279.51 | 2019-2025 | Rexulti |
| Allergan, INC. | $279.35 | 2019-2020 | |
| Alkermes, INC. | $258.09 | 2021-2024 | Lybalvi, Aristada, Aristada Initio |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $202.19 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $159.99 | 2019-2025 | Dyanavel Xr |
| Almatica Pharma LLC | $127.26 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Adlon Therapeutics L.P. | $105.96 | 2020-2021 | |
| Bausch Health US, LLC | $95.45 | 2022-2025 | Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $90.03 | 2025 | Cobenfy |
| Neos Therapeutics, LP | $89.26 | 2019-2025 | Adzenys Xr-Odt |
| Eisai INC. | $76.03 | 2020-2021 | |
| Shire North American Group INC | $59.51 | 2019 | |
| Collegium Pharmaceutical, INC. | $31.05 | 2025 | Jornay Pm |
| Neuronetics, INC. | $23.40 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $19.82 | 2021 | |
| Sage Therapeutics, LLC | $18.86 | 2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $15.25 | 2022 | |
| Rhodes Pharmaceuticals L.P. | $14.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.